KR20210100667A - 신경 또는 정신 장애의 치료 방법 - Google Patents

신경 또는 정신 장애의 치료 방법 Download PDF

Info

Publication number
KR20210100667A
KR20210100667A KR1020217020606A KR20217020606A KR20210100667A KR 20210100667 A KR20210100667 A KR 20210100667A KR 1020217020606 A KR1020217020606 A KR 1020217020606A KR 20217020606 A KR20217020606 A KR 20217020606A KR 20210100667 A KR20210100667 A KR 20210100667A
Authority
KR
South Korea
Prior art keywords
disorder
patient
formula
compound
adverse events
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217020606A
Other languages
English (en)
Korean (ko)
Inventor
세스 캐봇 홉킨스
Original Assignee
선오비온 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선오비온 파마슈티컬스 인코포레이티드 filed Critical 선오비온 파마슈티컬스 인코포레이티드
Publication of KR20210100667A publication Critical patent/KR20210100667A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217020606A 2018-12-06 2019-12-05 신경 또는 정신 장애의 치료 방법 Ceased KR20210100667A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862776247P 2018-12-06 2018-12-06
US62/776,247 2018-12-06
US201962829796P 2019-04-05 2019-04-05
US62/829,796 2019-04-05
PCT/US2019/064646 WO2020118032A1 (en) 2018-12-06 2019-12-05 Methods of treating neurological and psychiatric disorders

Publications (1)

Publication Number Publication Date
KR20210100667A true KR20210100667A (ko) 2021-08-17

Family

ID=69024675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020606A Ceased KR20210100667A (ko) 2018-12-06 2019-12-05 신경 또는 정신 장애의 치료 방법

Country Status (9)

Country Link
US (3) US20200179336A1 (enExample)
EP (1) EP3890726A1 (enExample)
JP (2) JP2022511509A (enExample)
KR (1) KR20210100667A (enExample)
CN (2) CN118576586A (enExample)
AU (2) AU2019394956B2 (enExample)
CA (1) CA3122261A1 (enExample)
MX (1) MX2021006553A (enExample)
WO (1) WO2020118032A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
KR20230003503A (ko) 2020-04-14 2023-01-06 선오비온 파마슈티컬스 인코포레이티드 신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민
US20220165391A1 (en) * 2020-11-25 2022-05-26 Kyndryl, Inc. Multi-stage treatment recommendations
KR20240110935A (ko) * 2021-09-23 2024-07-16 스미토모 파마 아메리카, 인크. 대사 장애를 치료하는 방법
CA3260160A1 (en) 2022-08-30 2024-03-07 Sumitomo Pharma America, Inc. ULOTARONT FOR THE ADJUVANT TREATMENT OF MAJOR DEPRESSIVE DISORDER
AU2023358704A1 (en) 2022-10-13 2025-05-29 Sumitomo Pharma America, Inc. Methods of reducing physical dependence to neuropsychiatric treatments
WO2024092070A1 (en) * 2022-10-28 2024-05-02 Sumitomo Pharma America, Inc. Ulotaront for treating anxiety and associated conditions
CN120187422A (zh) 2022-11-15 2025-06-20 住友制药美国公司 使用ulotaront转换神经精神病学药物的方法
CN115754079B (zh) * 2022-11-28 2025-04-04 合肥和合医疗科技有限公司 一种同时检测7种精神药物及其代谢产物含量的方法
CN117594119B (zh) * 2024-01-17 2024-05-10 北京大学第六医院 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置
WO2025252814A1 (en) 2024-06-04 2025-12-11 Duc Duy Vo Methods for treating trace amine-associated receptor 1 (taar1)-associated diseases or disorders comprising administration of novel taar1 agonists or pharmaceutical compositions thereof
WO2026015878A1 (en) * 2024-07-12 2026-01-15 Mindx Therapeutics, Inc. A new combination therapy for treatment-resistant depression in patients with co-morbid metabolic syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193761B (zh) 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
EP3582815A1 (en) * 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
WO2019161236A1 (en) * 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders

Also Published As

Publication number Publication date
CA3122261A1 (en) 2020-06-11
AU2019394956B2 (en) 2025-05-08
MX2021006553A (es) 2021-09-08
CN118576586A (zh) 2024-09-03
US20240350453A1 (en) 2024-10-24
AU2025213591A1 (en) 2025-08-21
JP2025024102A (ja) 2025-02-19
JP2022511509A (ja) 2022-01-31
US20200179336A1 (en) 2020-06-11
CN113271936A (zh) 2021-08-17
US20250312308A1 (en) 2025-10-09
AU2019394956A1 (en) 2021-06-17
WO2020118032A1 (en) 2020-06-11
EP3890726A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US20240350453A1 (en) Methods of treating neurological and psychiatric disorders
US11738002B2 (en) Methods of treating neurological and psychiatric disorders
AU2019213454B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
JP2022105159A (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
CN115776894A (zh) T型钙通道调节剂的使用方法
JP2022535893A (ja) 放出調節製剤およびその使用
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
US20220323409A1 (en) Modified release formulations and uses thereof
HK40057761A (en) Methods of treating neurological and psychiatric disorders
EP4121434A1 (en) Crystalline forms of squalamine
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000